
1. j viral hepat. 2019 sep;26(9):1127-1138. doi: 10.1111/jvh.13132. epub 2019 jul
11.

efficacy safety two-drug direct-acting antiviral agent regimen ruzasvir 
180 mg uprifosbuvir 450 mg 12 weeks adults chronic hepatitis c
virus genotype 1, 2, 3, 4, 5 6.

lawitz e(1), gane e(2), feld jj(3), buti m(4), foster gr(5), rabinovitz m(6),
burnevich e(7), katchman h(8), tomasiewicz k(9), lahser f(10), jackson b(10),
shaughnessy m(10), klopfer s(10), yeh ww(10), robertson mn(10), hanna gj(10),
barr e(10), platt hl(10); c-breeze-2 study investigators.

collaborators: gordon sc, lawitz ej, ruane pj, sahota a, terrault na, tsai n,
kalathil sc, reddy g, ghesquiere w, borgia s, conway b, feld j, tsoi k, cooper
cl, ghali pm, thompson ajv, panero jlc, ferret slmb, franinan lm, de los angeles 
castro iglesias m, brown a, agarwal k, foster g, cramp m, zuckerman e, veitsman
e, cohen m, lurie y, ari zb, janczewska e, szymczak a, halota w, flisiak r,
mahomed a, sonderup mw, punt ze, kgomo mk, bernhardi dc, burnevich ez, kizhlo s.

author information: 
(1)texas liver institute, university texas health san antonio, san antonio,
texas.
(2)auckland clinical studies, auckland, new zealand.
(3)toronto centre liver disease, university toronto, toronto, ontario,
canada.
(4)liver unit hospital universitari vall d'hebron centro de investigación
biomédica en red de enfermedades hepáticas digestivas (ciberehd) del instituto 
de salud carlos iii, barcelona, spain.
(5)queen mary university, london, uk.
(6)university pittsburgh medical center, university pittsburgh, pittsburgh,
pennsylvania.
(7)i.m. sechenov first moscow state medical university, moscow, russia.
(8)tel-aviv sourasky medical center, tel aviv, israel.
(9)medical university lublin, lublin, poland.
(10)merck & co., inc., kenilworth, new jersey.

ruzasvir (mk-8408, ns5a inhibitor) uprifosbuvir (mk-3682, nonstructural 
protein 5b nucleotide inhibitor) highly potent direct-acting antiviral agents
for treatment hepatitis c virus (hcv) infection. phase iii clinical
trial evaluating two-drug combination ruzasvir 60 mg plus  uprifosbuvir
450 mg suggested suboptimal efficacy certain hcv genotypes (c-breeze 1;
nct02759315). aim present study evaluate efficacy and
safety ruzasvir combination uprifosbuvir administered higher dose
than assessed earlier study (c-breeze 2: nct02956629/merck protocol
pn041). treatment-naïve interferon (with without ribavirin)-experienced
participants without compensated cirrhosis enrolled. all
participants received ruzasvir 180 mg plus uprifosbuvir 450 mg daily for
12 weeks. primary objectives proportion participants hcv rna
<15 lu/ml 12 weeks end study therapy (svr12), safety and
tolerability study drug. overall, 282 participants enrolled. svr12
(n/n) 91.3% (42/46) participants infected hcv genotype (gt) 1a; gt1b,
96.7% (29/30); gt2, 91.5% (43/47); gt3, 73.8% (45/61); gt4, 98.2% (55/56); gt5,
100.0% (18/18); gt6, 90.9% (20/22). adverse events (aes) reported by
61.3% participants; drug-related aes reported 33.3%. frequent
(≥5% participants) drug-related aes participants fatigue (7.8%)
and headache (7.4%). conclusion, two-drug combination ruzasvir 180 mg
plus uprifosbuvir 450 mg 12 weeks highly effective well tolerated 
participants infected hcv gt1, gt2, gt4, gt5 gt6, lower efficacy 
in gt3-infected persons.

© 2019 john wiley & sons ltd.

doi: 10.1111/jvh.13132 
pmid: 31108015  [indexed medline]

